The majority of patients with acute myeloid leukaemia (AML) are elderly. Advancements in
supportive care and regimen intensification have resulted in improvements in clinical …

While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML),
the disease has a high probability of relapse. Strategies to prevent relapse involve …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic
syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and …

Seventy to 80% of patients with acute myeloid leukemia (AML) achieve complete remission
following intensive chemotherapy, but more than 50% of patients in remission subsequently …

Whereas in younger patients diagnosed with acute myeloid leukemia (AML) treatment is
straightforward and the goal is cure, the optimal treatment decision for older adults remains …

Gemtuzumab ozogamicin (fGO), a humanized anti‐CD33 monoclonal antibody linked to
calicheamicin in combination with intensive chemotherapy gives high response rates in …

The bone marrow (BM) niche encompasses multiple cells of mesenchymal and
hematopoietic origin and represents a unique microenvironment that is poised to maintain …

The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The
complete response (CR) rate after relapse is around 25%, with 11% of patients still alive …

Outcome of patients with primary refractory/relapsed (R/R) acute myeloid leukemia (AML)
remains dismal. Herein, we present a retrospective monocentric study of 24 very high-risk …